Obesity has become pharma’s first truly consumer-driven Rx market. What does that mean for segmentation, launch strategy, and commercial models? Our pharma expert Martin Sorgenfrei, consumer health expert Christian Ring-Knudsen, and FMCG expert Benedikt Schmitz outline how healthcare companies need to rethink their approach to compete.
The GLP-1 weight loss market has transformed treatment paradigms and exposed structural limits in pharma’s commercial model, raising questions about its fit for today’s market.
For decades, almost all innovative prescription medicines followed a familiar logic. They were primarily payer-funded. They remained largely absent from mainstream cultural discourse. Physicians controlled patient access and awareness.
Obesity has changed that model.
Weight loss therapies now feature across news outlets, social media, and popular culture. Patients arrive at physician offices informed and opinionated, often requesting specific treatments by name. Medical necessity remains paramount, but demand dynamics have shifted. Patients influence prescribing decisions and explore alternative access channels, from pharmacy-led pathways to online platforms.
This shift changes how demand forms and how value is assessed. We believe this marks the beginning of a fundamentally different commercial logic for certain prescription categories. Yet before redesigning channels and execution models, companies must clarify what defines a winning value proposition in a consumer-driven obesity market.
In obesity, patient-centricity has evolved into something more demanding: consumer-centricity. Patients remain patients, but they behave like consumers. Markets reward companies that adapt quickly to this new market logic.
Why you need to rethink the “consumer” in obesity
In pharma, the terms “consumer” or “shopper” can feel misaligned with the regulatory and ethical standards governing prescription medicines. Obesity therapies are subject to strict oversight and clinical requirements. That will not change.
What has changed is observable customer behavior. Patients actively seek treatment, pay out of pocket at meaningful scale, gather information across channels including word of mouth from friends or public figures, form perceptions before meeting a physician, and weigh trade-offs beyond clinical endpoints. They evaluate value in personal, practical, and financial terms.
In most industries, such behavior would immediately trigger consumer-grade commercial thinking. In pharma, many organizations still rely on models built for payer- and provider-driven markets. We believe that, in obesity, this gap has strategic consequences. The category is attracting rapid innovation and new entrants. Competitive intensity will increase, and speed and precision will be pivotal for share capture.
Segmentation as a source of advantage in the weight loss Rx market
Pharma has deep expertise in understanding payers, prescribers, and providers. That capability, while essential, no longer captures the full decision landscape in obesity. Patients exert their own influence on treatment choice and demand. Winning therefore requires the same rigor in understanding patients as decision-makers that pharma has long applied to traditional stakeholders. Competitive advantage begins with that segmentation.
Clinical segmentation - BMI thresholds, comorbidities, guideline eligibility - does not explain why patients seek treatment at a given moment, how they define success which trade-offs they accept, or how they evaluate price relative to perceived benefit.
Effective segmentation focuses on behavioral characteristics and maps motivation, beliefs, willingness to use and pay for treatment, and trusted sources of information. It shows how patients make decisions rather than how clinicians classify them.
But segmentation alone is not enough. It must lead to differentiated offerings that deliberately match distinct patient segments. Otherwise, the expanding toolbox of options - oral versus injectable formats, varied dosing intervals (daily, weekly, or monthly regimens), mono versus combination therapies - risks being deployed without strategic focus. It’s not a winning consumer strategy to try to serve everyone with everything, especially in FMCG. Leadership comes from clearly defining which offerings serve whom and why they are uniquely relevant to that segment.
Without segment-driven differentiation, you can execute flawlessly within a traditional model and still miss the market.
If you are already in market
Early entry does not guarantee durable leadership. Several in-market players are discovering that excellence in HCP engagement and payer negotiation does not automatically translate into patient uptake.
The priority now is integration. Highest quality consumer insights must inform brand positioning, pricing architecture, channel strategy, and experience design. Go-to-market models should begin with patient consideration and extend through prescription and prescriber engagement.
In a market where patients form narratives before they meet a physician, field force activity alone cannot drive market performance. Demand develops upstream. Omnichannel orchestration and the right targeting now sit at the core of competitive positioning in an increasingly hyper-competitive market.
Brand clarity is equally critical. Patients rarely anchor decisions solely on percentage weight loss after 52+ weeks as observed in pivotal trials under controlled conditions. They respond to relevance, credibility, trust, and fit with their personal lives and needs, and anticipated side effects. Clinical performance establishes legitimacy, but it is not a complete brand promise.
If you are preparing to launch
If you are preparing to launch in obesity, ask whether your launch model reflects the market you are entering.
Traditional HCP-driven playbooks require adjustment. Payer and physician value propositions remain indispensable. But a distinct consumer value proposition is equally necessary. We believe launch excellence in obesity will depend on how early and how clearly this proposition is defined.
Where do patients first encounter the category? How does your product enter their evoked set? How will category and product perceptions form before a prescribing decision is made?
Without a defined consumer proposition, it is the competitors – and the market – who will define the narrative for you.
If you are considering entry
For companies still evaluating entry, the window for capability building is narrowing. By the time new assets reach the market, competition will intensify, brand positions will be firmly established, and patient expectations will be clearer.
Strategic choices cannot wait until pre-launch. You need early clarity on:
- Which patient segments do you intend to win
- How you will differentiate beyond the molecule
- What access logic - including cash-pay dynamics - will apply
- Which consumer-centric capabilities must be built well in advance
Delaying these decisions limits strategic flexibility.
The real risk - and the opportunity for you
This is not about simply importing FMCG tactics into healthcare. Companies must design a commercial model that reflects how this prescription category functions today taking new market realities into account.
Most organizations recognize the shift in demand. The risk lies in responding incrementally while competitors redesign their go-to-market and commercial model at a structural level.
Leadership in the obesity market will favor companies that act decisively, embed consumer dynamics into their commercial model, and build capabilities before competitors do.
Capturing this opportunity requires new approaches to patient and market segmentation, value definition, demand activation, and alignment of brand, price, and access.
In upcoming articles, we will explore what this structural shift means in practice: How can patient and market segmentation be redefined beyond clinical criteria? Which distinct patient segments are emerging - and how can sub-markets be identified and prioritized? How should winning brands be positioned in an increasingly crowded obesity space? How can value be defined differently for specific patient segments? And which demand activation models truly reflect how patients engage with this category today?
We believe that bringing these questions to life requires combining deep pharma and consumer health expertise with proven FMCG best practices in segmentation, branding, pricing, and omni-channel activation - thoughtfully adapted to the regulatory and ethical realities of prescription healthcare.
If you would like to discuss how these approaches could translate into your obesity strategy and commercial model, we encourage you to reach out to our experts to explore what this could mean for your organization.
